Vera Therapeutics' Kidney Disease Drug Shows Promising 46% Proteinuria Reduction in Phase 3 Trial
TL;DR Summary
Vera Therapeutics announced positive Phase 3 trial results for its kidney disease drug atacicept, which significantly reduced proteinuria in patients with IgA nephropathy, supporting a potential FDA submission later this year.
Topics:business#atacicept#clinical-trial#healthcare#iga-nephropathy#kidney-disease#vera-therapeutics
- Vera Therapeutics reports positive results from trial of kidney disease drug statnews.com
- Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy Yahoo Finance
- Breakthrough: New Drug Cuts Kidney Disease Protein by 46% in Phase 3 Trial - FDA Filing Next Stock Titan
- Vera shares skyrocket as kidney disease drug succeeds in late-stage trial MSN
- Scotiabank Adjusts Price Target on Vera Therapeutics to $65 From $55, Maintains Outperform Rating marketscreener.com
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
88%
269 → 31 words
Want the full story? Read the original article
Read on statnews.com